| |
Univariate model
|
Multivariate model
|
|---|
|
Factor
|
HR (95%CI)
|
P value
|
HR (95%CI)
|
P value
|
|---|
|
Age (61 ≤)
|
2.2 (0.8–6.7)
|
0.15
|
-
|
-
|
|
Sex (male)
|
2.6 (0.7–9.3)
|
0.14
|
-
|
-
|
|
Stage III, IV
|
7.6 (1.0–5.8)
|
0.15
|
-
|
-
|
|
Extranodal site (2 ≤)
|
1.7 (0.6–4.8)
|
0.35
|
-
|
-
|
|
LDH (> upper normal limit)
|
1.8 (0.5–5.8)
|
0.34
|
-
|
-
|
|
Performance status (2–4)
|
2.8 (1.0–8.1)
|
0.05
|
-
|
-
|
|
RDI (CPA+DOX) per 0.1
|
0.7 (0.6–0.9)
|
0.02*
|
0.8 (0.6–1.0)
|
0.08
|
|
IPI (high/high intermediate)
|
4.7 (1.3–17)
|
0.02*
|
3.8 (1.0–14)
|
0.05
|
|
Albumin (3.5 mg/dl ≤)
|
0.7 (0.4–1.2)
|
0.20
|
-
|
-
|
|
Prophylactic G-CSF
|
1.6 (0.5–4.9)
|
0.44
|
-
|
-
|
- HR: hazard ratio; CI: confidence interval; RDI: relative dose intensity; CPA: cyclophosphamide; DOX: doxorubicin; G-CSF: granulocyte colony-stimulating factor
